• Vaccine Ontology ID: VO_0011463
• Type: Subunit vaccine
• Status: Research
• URE gene engineering:
  • Type: Recombinant protein preparation
  • Detailed Gene Information: Click Here.
• Adjuvant:
  • VO ID: VO_0001237
• Immunization Route: Subcutaneous injection

• Vaccine Ontology ID: VO_0011461
• Type: DNA vaccine
• Status: Research
• pra gene engineering:
  • Type: DNA vaccine construction
  • Detailed Gene Information: Click Here.
• Vector: pVR1012 (Awasthi et al., 2005)
• Immunization Route: Intramuscular injection (i.m.)

• Vaccine Ontology ID: VO_0011490
• Type: Subunit vaccine
• Status: Research
• GEL1 gene engineering:
  • Type: Recombinant protein preparation
  • Detailed Gene Information: Click Here.
• Adjuvant:
  • VO ID: VO_0001237
  • Description: CpG ODN (Integrated DNA Technologies, Inc., Coralville, Iowa) (Delgado et al., 2003).
• Immunization Route: Intraperitoneal injection (i.p.)

• Vaccine Ontology ID: VO_0011460
• Type: Subunit vaccine
• Status: Research
• pmp1 gene engineering:
  • Type: Recombinant protein preparation
  • Detailed Gene Information: Click Here.
• Adjuvant:
  • VO ID: VO_0001250
  • Description: Monophosphoryl lipid A-stable emulsion (MPL-SE) adjuvant (Orsborn et al., 2006)
• Immunization Route: Intramuscular injection (i.m.)

Mouse Response

• Host Strain: BALB/c
• Vaccination Protocol: Mice each were immunized s.c. with recombinant protein (15 μg of rURE) or bovine serum albumin for control group (Li et al., 2001).
• Challenge Protocol: Mice were challenged by the i.p. route at 14 days after the last protein immunization or 30 days after the last DNA immunization. The inoculum contained 100 viable arthroconidia in 100 μl of PBS (Li et al., 2001).
• Efficacy: The rURE-immune mice showed significantly lower counts of C. immitis in both lungs and spleens compared to control mice immunized with BSA plus CpG ODN (Li et al., 2001).

Mouse Response

• Host Strain: C57BL6
• Vaccination Protocol: C57BL6 mice were anesthetized by i.m. injection of ketamine-xylazine (75 µg/g and 10 µg/g body weight, respectively). Transfected DCs (1–1.5 x 10^6 per 30 µl) were intranasally administered in both nares alternately. Comparative controls were Ag2/PRA plasmid DNA alone, nontransfected cells, and cells transfected with the vector plasmid alone. The immunization was performed twice at an interval of 1 wk (on days 0 and 7). The second immunization was given to boost the immune response (Awasthi et al., 2005).
• Challenge Protocol: The immunized mice were infected with C. posadasii either i.p. or intranasally. Intranasal challenge was given on day 19 with 30 arthroconidia per 30 µl of saline, whereas the i.p. challenge was given on day 14 with 2500 arthroconidia per 500 µl of saline. The infected mice become symptomatic around day 9–10 and start dying on day 11. Therefore, the mice were sacrificed on 10th day of infection, and their lungs and spleens were collected (Awasthi et al., 2005).
• Efficacy: Upon necropsy after 10 days of infection, fungal burden in lung and spleen of immunized mice was significantly reduced as compared with the control animals. The lung tissue homogenates of immunized animals showed higher levels of IFN-gamma. Histologically, lung tissues of immunized mice were in better condition than the control mice (Awasthi et al., 2005).

Mouse Response

• Host Strain: BALB/c, C57BL/6
• Vaccination Protocol: Mice were immunized subcutaneously (s.c.) with rGel1p plus adjuvant. The mice were then boosted by s.c. immunization 14 days later with the same amount of immunogen plus adjuvant (Delgado et al., 2003).
• Challenge Protocol: The animals were subsequently challenged with 100 viable arthroconidia by the i.p. route 2 weeks after the last immunization and then sacrificed 12 days later to determine the residual CFU in the lungs and spleen (Delgado et al., 2003).
• Efficacy: rGel1p-immune mice infected with the pathogen showed a significant reduction in fungal burden and increased survival compared to nonimmune mice (Delgado et al., 2003).

Mouse Response

• Host Strain: C57BL/6
• Vaccination Protocol: Mice were immunized subcutaneously with 1, 5, or 50 μg rPmp1 with monophosphoryl lipid A-stable emulsion (MPL-SE) adjuvant on day 0 and day 14. Control mice received adjuvant only (Orsborn et al., 2006).
• Challenge Protocol: Four weeks after boosting (day 42), the mice were infected intraperitoneally with 310 arthroconidia and sacrificed 2 weeks later (Orsborn et al., 2006).
• Efficacy: Vaccination with PMP1 elicited significant protection in mice and a reduction in colonization of organs by Coccidioides (Orsborn et al., 2006).